Dive into the archives.
- First 10-Year Follow-Up Shows That AVONEX® Leads To Long-Term Benefits In Early MS Pts
July 4, 2009
Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study). Based on the CHAMPS study, AVONEX was granted approval for use in patients who [...]
- Hot off the AAN Press: Tysabri Promotes Remyelination
July 4, 2009
Biogen Idec (NASDAQ: BIIB) and Elan Corporation (NYSE: ELN) announced results of a study demonstrating that Tysabri® (natalizumab) promoted regeneration and stabilization of damage done to the myelin sheath, as measured by advanced MRI technology. Damage to the myelin sheath causes the symptoms of multiple sclerosis (MS). Additional posters were presented during the [...]
- Hot off the AAN Press (belatedly): High Doses of Vitamin D Cut MS Relapses
April 28, 2009 (Seattle) — High doses of vitamin D dramatically cut the relapse rate in people with multiple sclerosis, a study shows.
Sixteen percent of 25 people with multiple sclerosis (MS) given an average of 14,000 international units (IU) of vitamin D a day for a year suffered relapses, says Jodie Burton, MD, a [...]
- Hot off the AAN press: Adding Steroid to Interferon May Slow Disease Activity
SEATTLE, April 30 — Adding methylprednisolone (Medrol) to Interferon-beta-1a (Avonex) treatment for multiple sclerosis may reduce disease activity better than interferon alone, researchers here said.
The combination of steroid and Interferon failed to meet its primary endpoint of time-to-sustained-progression in the MECOMBIN randomized controlled trial. But a host of secondary and tertiary outcomes — including functionality [...]
- Hot off the AAN Press: Novantrone Linked to Many More Cases of Leukemia
April 30, 2009
This morning at the American Academy of Neurology’s conference in Seattle, a report was released reporting that there is a significantly increased risk of leukemia from the drug mitoxantrone (Novantrone) in patients with progressive forms of multiple sclerosis (MS).
Novantrone has always had significant health risks. When patients receive a dosage increase they must [...]
- Hot off the AAN Press: Cladribine Reduces Relapses, Disability, Disease Progression
April 29, 2009
Merck KGaA on Wednesday presented detailed results from a previously announced Phase III study of investigational oral multiple sclerosis drug cladribine at the American Academy of Neurology annual conference. The findings demonstrated that annual short-course treatment with cladribine significantly reduced the rate of clinical relapses, disability progression and brain lesions in patients [...]
- Hot off the AAN Press: Laquinimod, New Data, Novel MOA
New Data Illustrate Novel Mechanism OF Action of Laquinimod, an Oral Compound for the Treatment of Multiple Sclerosis
-Researchers Demonstrate Immunomodulatory Effects of Laquinimod on Disease Activity
Jerusalem, Israel, Lund, Sweden and Seattle, Washington, April 28, 2009 – Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from several new [...]
- Hot off the AAN Press: Fingolimod effective but safety an issue
UPDATE 3-Novartis MS drug effective but safety an issue
ZURICH, April 29 (Reuters) – Novartis AG said 80-83 percent of those taking its multiple sclerosis drug FTY720 are relapse-free compared with 69 percent on the leading current treatment, but it reported a new patient death.
Novartis said the patient died from aspiration pneumonia related to a [...]
- Hot off the AAN Press: Tysabri May Reverse MS Damage
UPDATE 1-Elan’s Tysabri may reverse MS damage, shares up
April 29 (Reuters) – Elan’s Tysabri drug may be able to reverse damage caused by multiple sclerosis, the Irish drugmaker and its U.S. partner Biogen Idec said on Wednesday, boosting Elan’s shares 10 percent.
Data released by the companies at the American Academy of Neurology showed Tysabri promoted [...]
- Hot off the AAN Press: Study Suggests Copaxone has Protective Effects
Long-Term Study with COPAXONE® Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
- New Data Presented at 61st Annual Meeting of the American Academy of Neurology -
JERUSALEM–New data presented today provided evidence that long-term treatment with COPAXONE® (glatiramer acetate injection) [...]
